Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 955-960

  Hu, Oliver Yoa Pu ^a   Tang, Hung Shang ^b   Lane, Hsien Yuan ^c   Chang, Wen Ho ^c   Hu, Teh Min ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; DEXTRORPHAN; MEDICONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DEMETHYLATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DETERMINATION; DRUG SALIVA LEVEL; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTITUSSIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; PHENOTYPE; SALIVA;

EID: 0031836582     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Duche JC, Querol-Ferrer V, Barre J, Mesangeau M and Tillement JP (1993) Dextromethorphan O-demethylation and dextrorphan glucuronidation in French population. Int J Clin Pharmacol Ther Toxicol 31:392-398.
2. Frèche JP, Dragacci S, Petit AM, Siest JP, Galteau MM and Siest G (1990) Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population. Eur J Clin Pharmacol 39:481-485.
3. Henthorn TK, Benitez J, Avram MJ, Martinez G, Llerena A, Cobaleda J, Krejcie TC and Gibbons RD (1989) Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 45:328-333.
4. Hildebrand. M, Seifert W and Reichenberger A (1989) Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36:315-318.
5. Hou ZY, Pickle LW, Meyer PS and Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolite phenotype. Clin Pharmacol Ther 49: 410-419.
6. Irshaid YM, Al-Hadidi HF and Rawashdeh NM (1993) Dextromethorphan O-demethylation polymorphism in Jordanians. Eur J Pharmacol 45:271-273.
7. Jacqz E, Dulac H and Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167-171.
8. Kupfer A, Schmid B and Praff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421-433.
9. Lam YWF and Rodriquez SY (1993) HPLC determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 15:300-304.
10. Lane HY, Deng HC, Huang SM, Hu WH, Chang WH and Hu OYP (1996) Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin Pharmacol Ther 60:696-698.
11. Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G and Pessayre D (1987) Polymorphism of dextromethorphan oxidation in French population. Br J Clin Pharmacol 24:676-679.
12. Larrey D, Babany G, Tinel M, Freneaux E, Amouyal G, Habersetzer F, Letteron P and Pessayre D (1989) Effect of liver disease on dextromethorphan oxidation capacity and phenotype: A study in 107 patients. Br J Clin Pharmacol 28:297-304.
13. Marinac JS, Foxworth JW and Willsie SK (1995) Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects. Ther Drug Monit 17:120-124.
14. Schmid B, Bircher J, Preisig R and Kupfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
15. Straka RJ, Hansen SR and Walker PF (1995) Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin Pharmacol Ther 58:29-34.
16. Wang SL, Huang JD, Lai MD, Liu BH and Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.